Human Papillomavirus (HPV) - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Human Papillomavirus (HPV) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Human Papillomavirus (HPV) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Human Papillomavirus (HPV) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Human Papillomavirus (HPV) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Human Papillomavirus (HPV) outlook. It also includes the explanation of changing trends of epidemiology outlining the Human Papillomavirus (HPV) scenario.

Human Papillomavirus (HPV) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Human Papillomavirus (HPV) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Human Papillomavirus (HPV) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Human Papillomavirus (HPV) Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Human Papillomavirus (HPV)

Key assessments

- Patient Segmentation in Human Papillomavirus (HPV)

- Human Papillomavirus (HPV) Risk & Burden

- Factors driving growth in a specific Human Papillomavirus (HPV) patient population

Human Papillomavirus (HPV) - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Human Papillomavirus (HPV) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Human Papillomavirus (HPV) in 2016
2.2. Patient Share Distribution of Human Papillomavirus (HPV) in 2028
3. Disease Background and Overview: Human Papillomavirus (HPV)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Human Papillomavirus (HPV) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Human Papillomavirus (HPV) in 7MM - By Countries
5. Epidemiology of Human Papillomavirus (HPV) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
5.1.3. Sub-Type Specific cases of the Human Papillomavirus (HPV) *
5.1.4. Sex- Specific Cases of the Human Papillomavirus (HPV) *
5.1.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
5.4.3. Sub-Type Specific cases of the Human Papillomavirus (HPV) *
5.4.4. Sex- Specific Cases of the Human Papillomavirus (HPV) *
5.4.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
5.5.3. Sub-Type Specific cases of the Human Papillomavirus (HPV) *
5.5.4. Sex- Specific Cases of the Human Papillomavirus (HPV) *
5.5.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
5.6.3. Sub-Type Specific cases of the Human Papillomavirus (HPV) *
5.6.4. Sex- Specific Cases of the Human Papillomavirus (HPV) *
5.6.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
5.7.3. Sub-Type Specific cases of the Human Papillomavirus (HPV) *
5.7.4. Sex- Specific Cases of the Human Papillomavirus (HPV) *
5.7.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
5.8.3. Sub-Type Specific cases of the Human Papillomavirus (HPV) *
5.8.4. Sex- Specific Cases of the Human Papillomavirus (HPV) *
5.8.5. Diagnosed Cases of the Human Papillomavirus (HPV)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Human Papillomavirus (HPV)
5.9.3. Sub-Type Specific cases of the Human Papillomavirus (HPV) *
5.9.4. Sex- Specific Cases of the Human Papillomavirus (HPV) *
5.9.5. Diagnosed Cases of the Human Papillomavirus (HPV)
6. Unmet Needs of the Human Papillomavirus (HPV)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Human Papillomavirus (HPV) in 7MM
Table 2: Total Prevalent/Incident Cases of the Human Papillomavirus (HPV) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Human Papillomavirus (HPV) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Human Papillomavirus (HPV) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Human Papillomavirus (HPV) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Human Papillomavirus (HPV) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Human Papillomavirus (HPV) in France (2016-2028) *
Table 14: Diagnosed Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Human Papillomavirus (HPV) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Human Papillomavirus (HPV) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Human Papillomavirus (HPV) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Human Papillomavirus (HPV) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Human Papillomavirus (HPV) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Human Papillomavirus (HPV) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Human Papillomavirus (HPV) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Human Papillomavirus (HPV) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Human Papillomavirus (HPV) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Human Papillomavirus (HPV) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Human Papillomavirus (HPV) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Human Papillomavirus (HPV) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Human Papillomavirus (HPV) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Human Papillomavirus (HPV) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Human Papillomavirus (HPV) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Human Papillomavirus (HPV) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Human Papillomavirus (HPV) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Human Papillomavirus (HPV) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Human Papillomavirus (HPV) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Human Papillomavirus (HPV) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Human Papillomavirus (HPV) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Human Papillomavirus (HPV) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Human Papillomavirus (HPV) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Human Papillomavirus (HPV) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Human Papillomavirus (HPV) in Japan (2016-2028)

  • Global Sexually Transmitted Diseases Testing Professional Survey Report 2023, Forecast to 2028
    Published: 22-Dec-2023        Price: US 3280 Onwards        Pages: 106
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Sexually Transmitted Diseases Testing Market Research Report 2023, Forecast to 2028
    Published: 22-Dec-2023        Price: US 2680 Onwards        Pages: 130
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Sexually Transmitted Disease (STD) Testing Market Status and Outlook 2023-2028
    Published: 23-Nov-2023        Price: US 3160 Onwards        Pages: 102
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Sexually Transmitted Disease (Std) Testing Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Oct-2023        Price: US 3380 Onwards        Pages: 100
    Market Overview of Global Sexually Transmitted Disease (Std) Testing market: According to our latest research, the global Sexually Transmitted Disease (Std) Testing market looks promising in the next 5 years. As of 2022, the global Sexually Transmitted Disease (Std) Testing market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and pr......
  • Global Gonorrhea Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Oct-2023        Price: US 3380 Onwards        Pages: 98
    Market Overview of Global Gonorrhea Therapeutics market: According to our latest research, the global Gonorrhea Therapeutics market looks promising in the next 5 years. As of 2022, the global Gonorrhea Therapeutics market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Gonorrhea is a sexually transmitted disease (STD) caused by the bacterium Neisseria gonorrhea. It tends to infect the urethra......
  • Global Gonorrhea Therapeutics Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 89
    Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospec......
  • Global Sexually Transmitted Disease (STD) Testing Market Insights, Forecast to 2029
    Published: 01-Jun-2023        Price: US 4900 Onwards        Pages: 92
    Sexually Transmitted Disease (STD) Testing is a medical means of testing, prevention, and treatment of Sexually Transmitted Disease (STD). Market Analysis and Insights: Global Sexually Transmitted Disease (STD) Testing Market The global Sexually Transmitted Disease (STD) Testing market is projected to grow from US$ 225.3 million in 2023 to US$ 338.1 million by 2029, at a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period. The need for tests that eliminate ......
  • Global Sexually Transmitted Disease (STD) Testing Market Research Report 2023
    Published: 05-May-2023        Price: US 2900 Onwards        Pages: 89
    Sexually Transmitted Disease (STD) Testing is a medical means of testing, prevention, and treatment of Sexually Transmitted Disease (STD). Highlights The global Sexually Transmitted Disease (STD) Testing market was valued at US$ 225.3 million in 2022 and is anticipated to reach US$ 338.1 million by 2029, witnessing a CAGR of 7.0% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. The need ......
  • Global Gonorrhea Therapeutics Market Status and Outlook 2023-2028
    Published: 24-Apr-2023        Price: US 3160 Onwards        Pages: 104
    Neisseria gonorrhoeae infection can manifest as a variety of symptoms, which can affect the genitourinary system, anorectum, pharynx, and conjunctival area. Severe cases can lead to disseminated gonococcal infection, endocarditis and meningitis; in women, it is pelvic inflammatory disease (PID). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs